Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole

被引:48
作者
Beck, Katharina R. [1 ,2 ]
Baechler, Murielle [1 ,2 ]
Vuorinen, Anna [1 ,2 ]
Wagner, Sandra [3 ,4 ]
Akram, Muhammad [3 ,4 ]
Griesser, Ulrich [5 ]
Temml, Veronika [3 ,4 ]
Klusonova, Petra [1 ,2 ]
Yamaguchi, Hideaki [6 ]
Schuster, Daniela [3 ,4 ]
Odermatt, Alex [1 ,2 ]
机构
[1] Univ Basel, Swiss Ctr Appl Human Toxicol, Klingelbergstr 50, CH-4056 Basel, Switzerland
[2] Univ Basel, Div Mol & Syst Toxicol, Dept Pharmaceut Sci, Pharmazentrum, Klingelbergstr 50, CH-4056 Basel, Switzerland
[3] Univ Innsbruck, Inst Pharm Pharmaceut Chem, Innrain 80-82, A-6020 Innsbruck, Austria
[4] Univ Innsbruck, CMBI, Comp Aided Mol Design Grp, Innrain 80-82, A-6020 Innsbruck, Austria
[5] Univ Innsbruck, Inst Pharm Pharmaceut Technol, Innrain 80-82, A-6020 Innsbruck, Austria
[6] Meijo Univ, Dept Appl Biol Chem, Nagoya, Aichi 4688502, Japan
基金
奥地利科学基金会; 瑞士国家科学基金会;
关键词
11 beta-Hydroxysteroid dehydrogenase; Virtual screening; Reproductive toxicity; Itraconazole; Posaconazole; Glucocorticoid; BETA-HYDROXYSTEROID DEHYDROGENASE; APPARENT MINERALOCORTICOID EXCESS; INTRAUTERINE GROWTH RESTRICTION; ANTENATAL CORTICOSTEROIDS; GLUCOCORTICOID-RECEPTOR; LICORICE CONSUMPTION; PROSPECTIVE COHORT; HUMAN HYPERTENSION; ANTIFUNGAL AGENT; MULTIPLE COURSES;
D O I
10.1016/j.bcp.2017.01.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Impaired 11 beta-hydroxysteroid dehydrogenase type 2 (11(beta-HSD2)-dependent cortisol inactivation can lead to electrolyte dysbalance, hypertension and cardiometabolic disease. Furthermore, placental 11 beta-HSD2 essentially protects the fetus from high maternal glucocorticoid levels, and its impaired function has been associated with altered fetal growth and a higher risk for cardio-metabolic diseases in later life. Despite its important role, 11 beta-HSD2 is not included in current off-target screening approaches. To identify potential 11 beta-HSD inhibitors among approved drugs, a pharmacophore model was used for virtual screening, followed by biological assessment of selected hits. This led to the identification of several azole fungicides as 11 beta-HSD inhibitors, showing a significant structure-activity relationship between azole scaffold size, 11 beta-HSD enzyme selectivity and inhibitory potency. A hydrophobic linker connecting the azole ring to the other, more polar end of the molecule was observed to be favorable for 11 beta-HSD2 inhibition and selectivity over 11 beta-HSD1. The most potent 11 beta-HSD2 inhibition, using cell lysates expressing recombinant human 11 beta-HSD2, was obtained for itraconazole (IC50 139 +/- 14 nM), its active metabolite hydroxyitraconazole (IC50 223 +/- 31 nM) and posaconazole (IC50 460 +/- 98 nM). Interestingly, experiments with mouse and rat kidney homogenates showed considerably lower inhibitory activity of these compounds towards 11 beta-HSD2, indicating important species-specific differences. Thus, 11 beta-HSD2 inhibition by these compounds is likely to be overlooked in preclinical rodent studies. Inhibition of placental 11 beta-HSD2 by these compounds, in addition to the known inhibition of cytochrome P450 enzymes and P-glycoprotein efflux transport, might contribute to elevated local cortisol levels, thereby affecting fetal programming. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 92 条
[11]   METABOLIC CLEARANCE RATE, BLOOD PRODUCTION, INTERCONVERSION AND TRANSPLACENTAL PASSAGE OF CORTISOL AND CORTISONE IN PREGNANCY NEAR TERM [J].
BEITINS, IZ ;
BAYARD, F ;
ANCES, IG ;
KOWARSKI, A ;
MIGEON, CJ .
PEDIATRIC RESEARCH, 1973, 7 (05) :509-519
[12]   GLUCOCORTICOID EXPOSURE INUTERO - NEW MODEL FOR ADULT HYPERTENSION [J].
BENEDIKTSSON, R ;
LINDSAY, RS ;
NOBLE, J ;
SECKL, JR ;
EDWARDS, CRW .
LANCET, 1993, 341 (8841) :339-341
[13]   Placental 11 beta-hydroxysteroid dehydrogenase: A key regulator of fetal glucocorticoid exposure [J].
Benediktsson, R ;
Calder, AA ;
Edwards, CRW ;
Seckl, JR .
CLINICAL ENDOCRINOLOGY, 1997, 46 (02) :161-166
[14]   FETAL OSTEOCALCIN LEVELS ARE RELATED TO PLACENTAL 11-BETA-HYDROXYSTEROID DEHYDROGENASE-ACTIVITY IN HUMANS [J].
BENEDIKTSSON, R ;
BRENNAND, J ;
TIBI, L ;
CALDER, AA ;
SECKL, JR ;
EDWARDS, CRW .
CLINICAL ENDOCRINOLOGY, 1995, 42 (05) :551-555
[15]  
Bevilacqua E, 2010, J MATERN-FETAL NEO M, V23, P244, DOI [10.1080/14767050903165222, 10.3109/14767050903165222]
[16]   Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2 [J].
Brown, RW ;
Chapman, KE ;
Kotelevtsev, Y ;
Yau, JLW ;
Lindsay, RS ;
Brett, L ;
Leckie, C ;
Murad, P ;
Lyons, V ;
Mullins, JJ ;
Edwards, CRW ;
Seckl, JR .
BIOCHEMICAL JOURNAL, 1996, 313 :1007-1017
[17]   P-glycoprotein in the placenta: Expression, localization, regulation and function [J].
Ceckova-Novotna, Martina ;
Pavek, Petr ;
Staud, Frantisek .
REPRODUCTIVE TOXICOLOGY, 2006, 22 (03) :400-410
[18]   Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma [J].
Chen, Baozhi ;
Vinh Trang ;
Lee, Alex ;
Williams, Noelle S. ;
Wilson, Alexandra N. ;
Epstein, Ervin H., Jr. ;
Tang, Jean Y. ;
Kim, James .
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) :866-876
[19]   Inhibition of angiogenesis by the antifungal drug itraconazole [J].
Chong, Curtis R. ;
Xu, Jing ;
Lu, Jun ;
Bhat, Shridhar ;
Sullivan, David J., Jr. ;
Liu, Jun O. .
ACS CHEMICAL BIOLOGY, 2007, 2 (04) :263-270
[20]   Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects [J].
Conte, John E., Jr. ;
Golden, Jeffrey A. ;
Krishna, Gopal ;
McIver, Marina ;
Little, Emily ;
Zurlinden, Elisabeth .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) :703-707